Based on their report at JPM in January I speculated that the clinical growth they are seeing will continue to see Illumina grow, despite a decline in research revenue. This seems to be playing out as expected.
This site does not allow itself to be embedded. You can still read it on the original site — the toolbar below keeps your place in the directory.
Based on their report at JPM in January I speculated that the clinical growth they are seeing will continue to see Illumina grow, despite a decline in research revenue.
Comments
Nothing yet. Say the first thing.
Sign in to join the conversation.